Provided by Tiger Trade Technology Pte. Ltd.

Acurx Pharmaceuticals, LLC*

6.63
+1.4227.26%
Post-market: 6.790.1600+2.41%19:59 EDT
Volume:7.80M
Turnover:52.02M
Market Cap:18.93M
PE:-1.25
High:7.54
Open:5.01
Low:5.01
Close:5.21
52wk High:21.00
52wk Low:1.33
Shares:2.86M
Float Shares:2.42M
Volume Ratio:1.38
T/O Rate:322.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.3200
EPS(LYR):-17.4507
ROE:-270.80%
ROA:-87.59%
PB:3.59
PE(LYR):-0.38

Loading ...

Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP)

TIPRANKS
·
Mar 14

Acurx Pharmaceuticals (ACXP) Gets a Buy from Alliance Global Partners

TIPRANKS
·
Mar 14

Acurx price target lowered to $10 from $20 at Alliance Global

TIPRANKS
·
Mar 14

Acurx Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 13

Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend

Reuters
·
Mar 13

Acurx Pharmaceuticals Q4 EPS $(0.73) Beats $(1.65) Estimate

Benzinga
·
Mar 13

Acurx Pharmaceuticals Q4 EPS USD -0.73

THOMSON REUTERS
·
Mar 13

Press Release: Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update

Dow Jones
·
Mar 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 13

Top Premarket Decliners

MT Newswires Live
·
Mar 12

Why Is Acurx Pharmaceuticals Stock Up Over 105% Today?

Benzinga_recent_news
·
Mar 12

Acurx Pharmaceuticals Inc expected to post a loss of $1.01 a share - Earnings Preview

Reuters
·
Mar 11

Acurx Pharmaceuticals: Effective April 1, 2026, CEO & Executive Chairman Salaries Reduced to $495,000, CFO Salary Reduced to $360,000 - SEC Filing

THOMSON REUTERS
·
Mar 09

Acurx Pharmaceuticals Inc - Approves Voluntary Reductions to Executive Base Salaries - SEC Filing

THOMSON REUTERS
·
Mar 09

Acurx Pharmaceuticals Inc - Trial Start-up for Rcdi to Begin This Month; First Patient Expected Q4 2026

THOMSON REUTERS
·
Mar 09

Acurx Announces New Ibezapolstat Clinical Trial Program in Patients With Recurrent Cdi That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. Difficile Infection

THOMSON REUTERS
·
Mar 09

Acurx Pharmaceuticals Inc - Program Ready to Advance to Phase 3 International Clinical Trials for Cdi

THOMSON REUTERS
·
Mar 09

Acurx Pharmaceuticals Inc. to discuss full year and fourth quarter financial results

Reuters
·
Feb 16

Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update

THOMSON REUTERS
·
Feb 16

Acurx files to sell 750,000 shares of common stock for holders

TIPRANKS
·
Feb 03